The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1

Learn more about AbbVie’s response to COVID-19

AbbVie's commitment to

Exceptional access &
patient support

Man in blue tank top holding up his arms in celebration

>9

out
of

10

COMMERCIAL PATIENTS HAVE
ACCESS TO SKYRIZI IN PsA2

Access is as of January 2022 and available through commercial insurance or through Skyrizi Complete if coverage is denied.*

Encourage your
patients to enroll in

DOWNLOAD OR EMAIL SKYRIZI COMPLETE ENROLLMENT AND PRESCRIPTION FORM

AFFORDABILITy

for commercial patients

ACCESS: No charge for eligible patients

experiencing initial insurance delay or denial for up to 24 months*

Exceptional 1:1 patient experience

when your patients enroll in Skyrizi Complete

*Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

Stay up to date on the latest SKYRIZI news and information


ROBUST JOINT SYMPTOM IMPROVEMENT

ACR20 (primary endpoint) at Week 241

4 DOSES PER YEAR

4 doses per year after 2 initiation doses at Weeks 0 and 4 (150 mg/dose)1